华夏时报记者 于娜 北京报道 百万元一台的"救命神器"ECMO，曾是外资垄断的高端赛道，如今正迎来国产替代的全面突围。 在政策扶持、技术突破与临床需求升级的多重驱动下，我国体外膜肺氧合（ECMO）行业正进入深度洗 牌期。这场洗牌打破了长期以来外资品牌垄断的市场格局，国产企业加速崛起，区域市场布局呈现新态 势，行业竞争逻辑从单一技术比拼转向综合服务能力较量。 弗若斯特沙利文最新发布的体外生命支持行业市场研究报告显示，2024年我国ECMO市场规模达9.6亿 元，预计2030年市场规模增至37.1亿元，2024年至2030年复合年增长率为25.2%；于2035年达到107.3亿 元。当前我国ECMO配置率极低，平均每280万人才配备1台，与发达国家差距显著，供需缺口背后蕴藏 着巨大发展潜力。 长征医疗技术团队源自中国航天科技（000901）集团，凭借多年积累的技术优势与跨领域技术转化经 验，将航天伺服控制技术、流场仿真、系统集成能力应用于高端医疗器械领域，形成了独特的技术壁 垒。其旗下辉昇-I型ECMO是世界第二款集成式设计，重量仅7.5kg，极大提升了设备的便携性，适用场 景覆盖更全面。此外，公司自主研发的赤水 ...

寒潮基本收尾，但寒意还在"发力"。1月22日杭州虽有阳光，但防风保暖稍一松懈，寒意就直往衣 缝里钻。 在一波暖潮的影响下，周五起气温将开启"腾飞"模式；但下周初弱冷空气又会来"串门"，届时将带 来弱降水和降温天气。总的来说，接下来的天气就是：先冷再暖后凉，冷暖交替反复。请大家务必根据 气温及时添减衣物。 "最近，门诊呼吸道疾病患者增加两成，慢阻肺、哮喘患者住院人数增加三成。"浙江中医药大学附 属第二医院（浙江省新华医院）呼吸与危重症医学科主任陈晔介绍，大部分患者是因流感病毒、合胞病 毒导致慢性阻塞性肺疾病急性加重。 市一医院急诊科副主任医师谢赟提醒，每年流感季，都有因不典型流感引发重症心肌炎的患 者。"生活中，并非所有流感都会出现高烧、肌肉酸痛等典型症状，像萌萌这样仅以低烧、乏力为表现 的不典型病例更容易被忽视，进而延误治疗。" 王维斯也提到，从以往接诊情况看，暴发性心肌炎患者的早期症状与感冒高度相似，但如果感冒后 出现胸闷、气短、心悸、极度乏力等症状，或是症状持续数日没有好转，甚至逐渐加重，一定要及时就 医，切勿自行用药硬扛。尤其是青少年、孕产妇、老年人及有基础疾病的人群，免疫力相对较弱，感染 后更易引发并 ...

Core Insights - The National High-Performance Medical Device Innovation Center released the "2025 Medical Device Industry Innovation Ecosystem Insights" list, highlighting emerging companies, institutions, individuals, and products in China's medical device industry [1] - The assessment covers the entire chain from technology research and development to market application, showcasing the innovative ecosystem of China's medical device industry for 2025 [1] Group 1: Assessment Framework - The evaluation system has evolved from a dual dimension of "companies + individuals" to a comprehensive framework covering seven dimensions, including companies, individuals, products, universities, hospitals, investment institutions, and industrial parks [2] - This comprehensive assessment network achieves full coverage of the innovation chain, industrial chain, and capital chain [2] Group 2: Achievements and Innovations - Over the past five years, the center has made significant breakthroughs in key technologies, including the world's first 5.0T whole-body MRI and the first domestic ECMO, positioning these innovations among the international top tier [2] - The center has completed the domestic manufacturing of ECMO within three years, achieving performance metrics on par with international counterparts, marking a significant milestone in the development of high-end medical equipment in China [2] Group 3: Technological Advancements - The center is focused on strengthening core components and key raw materials, achieving full-chain domestic production for high-performance AFE chips and high-precision medical nickel-titanium materials [3] - In the past five years, the center has undertaken over 120 national and local research tasks, filed 296 patents (with two-thirds being invention patents), and participated in the revision of 11 industry standards [3] Group 4: Strategic Contributions - The center has played a pivotal role in strategic research and planning, contributing to over 30 strategic studies and deeply engaging in the national high-end medical equipment "14th Five-Year" top-level strategic planning [3] - It provides substantial intellectual support for national strategies, government decision-making, industrial resource collaboration, and corporate strategic layout [3]

Core Viewpoint - The Chinese medical equipment industry is experiencing significant growth and innovation, marking a shift towards self-sufficiency and high-end manufacturing, which is transforming both domestic and global healthcare landscapes [1][2][3]. Industry Growth - During the 14th Five-Year Plan period, the medical equipment industry in China has achieved a compound annual growth rate of approximately 10.7%, with the market size expected to reach 1.35 trillion yuan by 2024, maintaining its position as the second-largest market globally [2]. - By the end of 2024, the number of medical device manufacturing companies in China is projected to exceed 33,000, representing a 27.8% increase compared to the end of the 13th Five-Year Plan [2]. Technological Advancements - The industry is advancing towards high-end and intelligent medical equipment, with innovations such as zero-magnetic medical imaging devices and integrated radiation therapy technologies being introduced [3]. - Since the beginning of the 14th Five-Year Plan, 315 innovative medical devices have been approved, with 272 of these being domestic products, accounting for 86.3% [3]. - Key technologies such as carbon ion therapy systems and artificial hearts have achieved domestic production, reversing the previous scenario where imported devices dominated the high-end market [3]. Clinical Applications - The integration of artificial intelligence and advanced imaging technologies is enhancing the capabilities of medical equipment, with over 1.045 million patent applications filed in the medical equipment sector during the 14th Five-Year Plan [4]. - Innovations like the full-body PET/CT scanner have significantly reduced scanning times and improved imaging capabilities, demonstrating the effectiveness of domestic innovations in clinical settings [4]. Policy Support and Infrastructure - The Chinese government has implemented multiple policies to promote high-quality development in the medical equipment sector, including key projects and planning documents aimed at enhancing research, industry, and application [6]. - Continuous improvements in grassroots medical facilities are being made, with significant upgrades in medical equipment conditions and accelerated construction of county-level medical communities [6]. Accessibility and Affordability - The emergence of domestic surgical robots has led to a noticeable decrease in equipment prices, enabling more county-level hospitals to perform robotic surgeries [8]. - Advanced technologies such as AI-assisted diagnostics and remote surgery systems are breaking geographical barriers, allowing patients in rural areas to access quality medical services [8]. Conclusion - The ultimate goal of the development of medical equipment is to benefit public health, with ongoing efforts to ensure that more patients can access and afford high-quality domestic medical equipment [9].

Core Viewpoint - The National Medical Products Administration (NMPA) is committed to promoting the innovative development of high-end medical devices in China, aiming to transition from a "big manufacturing country" to a "strong manufacturing country" in the medical equipment sector [1] Group 1: Policy and Strategic Initiatives - The NMPA has implemented top-level design and inter-departmental collaboration to enhance the medical device industry, including the issuance of the "14th Five-Year Plan for National Drug Safety and Promotion of High-Quality Development" and the "14th Five-Year Plan for Medical Equipment Industry Development" [2] - The establishment of two technical innovation cooperation platforms focusing on artificial intelligence medical devices and medical biomaterials aims to accelerate the transformation of scientific achievements in the medical device field [2] - The NMPA has introduced innovative review measures, such as moving technical reviews to the product development stage, particularly for high-end medical devices like ECMO and particle therapy systems [2] Group 2: Innovation and Market Growth - The NMPA has prioritized the approval of innovative medical devices, implementing special review procedures to expedite the market entry of urgently needed clinical products [2] - In recent years, the NMPA has approved 217 innovative medical devices and 130 innovative drugs, with 28 innovative medical devices approved in the first half of this year alone [3] - The Chinese medical device industry has experienced a compound annual growth rate of 10.54% over the past five years, positioning China as the second-largest medical device market globally [3] Group 3: E-commerce and Sales Trends - The rapid development of online sales has significantly boosted the sales of drugs and medical devices, with an estimated online sales revenue of 292.4 billion yuan in 2022, projected to exceed 350 billion yuan in 2023 [4]

Core Insights - The high cost of ECMO treatment is attributed to multiple factors including high equipment procurement costs, expensive consumables, operational and maintenance costs, and the impact of market supply and demand [1][2][3] - The average cost for ECMO treatment can exceed 200,000 yuan for two weeks, with daily expenses in the ICU exceeding 10,000 yuan [2][3] - The current market for ECMO in China is dominated by foreign brands, with significant reliance on imported equipment, which contributes to high treatment costs [2][4][6] Equipment and Technology - ECMO is a high-tech device used for severe heart and lung failure, providing external oxygenation and circulatory support [1][5] - The price of ECMO machines ranges from 1.5 million to 3.5 million yuan, with consumable costs averaging 50,000 to 70,000 yuan per use [2][3] - The technology and manufacturing processes for ECMO are complex, leading to high hardware costs and the need for specialized personnel for operation and maintenance [3][6] Market Dynamics - There is a significant disparity in ECMO availability between China and developed countries, with one ECMO machine available for every 2.8 million people in China compared to one for every 20,000 to 40,000 people in Germany [4] - The domestic ECMO market is beginning to see competition from local companies, with three firms receiving regulatory approval for their devices, marking a breakthrough in the industry [5][6] - Market share data indicates that as of 2024, major brands include Maquet, Shenzhen Hanno, and Jiangsu Saiteng, with Maquet holding the largest share at approximately 49.42% [6] Commercialization Challenges - The high costs associated with ECMO treatment have led to patient hesitance, creating barriers to wider adoption compared to developed nations [4][7] - The commercialization of domestic ECMO devices faces challenges including technology maturity, market education, and reimbursement approval [6][7] - Investment in the ECMO sector has decreased significantly since the peak during the COVID-19 pandemic, reflecting a more cautious approach from capital markets [6][7]

Core Viewpoint - The article discusses a complaint regarding the high cost of ambulance transfer for a critically ill child from a public hospital in Jiangxi to a hospital in Shanghai, highlighting issues related to pricing transparency and the involvement of private ambulance services [1][2][5]. Group 1: Incident Overview - A family complained to the health department about the 28,000 yuan fee charged by a private ambulance for an 800-kilometer transfer, which lacked detailed pricing and invoices [2][4]. - The public hospital explained that their ambulance could not operate out of the province, necessitating the use of a private service for the transfer of a patient requiring specialized equipment [3][4]. Group 2: Medical Transfer Context - Long-distance transfers of critically ill patients by ambulance are uncommon, with distances over 600 kilometers typically requiring alternative transport methods like high-speed trains [6][8]. - The use of specialized equipment such as ECMO (Extracorporeal Membrane Oxygenation) significantly increases transfer costs due to the complexity and high expense of the equipment involved [13][14]. Group 3: Pricing and Regulations - Different regions have established pricing standards for long-distance medical transfers, with some areas charging around 25 yuan per kilometer for ambulance services [11][12]. - The lack of standardized pricing and the prevalence of private ambulance services for interprovincial transfers raise concerns about transparency and regulation in the medical transport sector [24][26]. Group 4: Industry Trends - There is a growing demand for non-emergency medical transport services, with various provinces beginning to regulate and encourage private medical transport providers [34][36]. - The increasing complexity of medical transfers, especially for critically ill patients, necessitates a reevaluation of existing service models and pricing structures in the healthcare industry [32][35].

Core Viewpoint - Guangdong is transitioning from a "manufacturing province" to an "innovation powerhouse," driven by new production forces and capital market dynamics [1] Group 1: Industry Development - Guangdong's industrial development has evolved from processing trade to a manufacturing leader, and now to a technology innovation frontier [1] - The province faces challenges such as intensified market competition, rising labor costs, and external instability, necessitating structural adjustments and upgrades in its industries [1] Group 2: Role of Capital - Capital markets play a crucial role in Guangdong's industrial upgrade by acting as both "value discoverers" and "resource integrators," facilitating the restructuring and transition of industries [2] - Guangdong has over 12,000 private equity and venture capital funds, with a total scale of 2.47 trillion yuan, supporting technological entrepreneurship and industrial upgrades [2] Group 3: Case Studies - Companies like Midea have engaged in capital operations, acquiring firms such as KUKA to enter the robotics market, demonstrating the active role of capital in industry transformation [3] - The integration of resources by companies like Songfa and Foshan Lighting showcases how capital can help traditional industries innovate and expand into new sectors [3] Group 4: Economic Stability and Growth - The synergy between traditional and emerging industries, supported by capital, contributes to economic stability and creates sustainable growth points for the future [3]